All In Biotech

Drug Trial Radar · NCT04333420

Randomized, Controlled Study of IFX-1 in Patients With Severe COVID-19 Pneumonia

A Pragmatic Adaptive Randomized, Controlled Phase II/III Multicenter Study of IFX-1 in Patients With Severe COVID-19 Pneumonia

Last checked: Nov 19, 2026Latest source record: Jun 5, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 399 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

399

Actual

Start

Mar 31, 2020

Primary completion

Oct 31, 2021

Study completion Dec 1, 2021

Sponsor

Lead sponsor
InflaRx GmbHIndustry
Sponsor type
Industry
First posted
Apr 3, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Phase II \& Phase III: This is a pragmatic, adaptive, randomized, multicenter phase II/III study evaluating IFX-1 for the treatment of COVID-19 related severe pneumonia. The study consists of two parts: Phase II, an open-label, randomized, 2-arm phase evaluating best supportive care (BSC) + IFX-1 (Arm A) and BSC alone (Arm B); and Phase III, a double-blind, placebo-controlled, randomized phase comparing standard of care (SOC) + IFX-1 (Arm A) versus SOC + placebo-to-match (Arm B)

Conditions

  • Severe COVID-19 Pneumonia

Interventions

  • IFX-1 + BSCDrug

    Phase II study part: IFX-1 + BSC

  • BSCDrug

    Phase II study part: BSC

  • IFX-1 + SOCDrug

    Phase III study part: IFX-1 + SOC

  • Placebo + SOCDrug

    Phase III study part: Placebo + SOC

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase II: Relative Change From Baseline in Oxygenation Index in Supine Position at Day 5 (FAS)Time frame: Baseline and Day 5
  2. Phase III: 28-day All-cause Mortality (FAS)Time frame: Day 28

Locations

48 sites in 9 countries. Site status is shown where the registry gives one.

  • InflaRx Site #1107

    Aalst, Belgium

  • InflaRx Site #1102

    Brussels, Belgium

  • InflaRx Site #1104

    Leuven, Belgium

  • InflaRx Site #1106

    Lodelinsart, Belgium

  • InflaRx Site #1101

    Yvoir, Belgium

  • InflaRx Site #0301

    Belo Horizonte, Brazil

  • InflaRx Site #0302

    Campinas, Brazil

  • InflaRx Site #0305

    Criciúma, Brazil

  • InflaRx Site #0308

    Curitiba, Brazil

  • InflaRx Site #0304

    Porto Alegre, Brazil

  • InflaRx Site #0303

    São José, Brazil

  • InflaRx Site #0306

    São Paulo, Brazil

  • InflaRx Site #1011

    Grenoble, France

  • InflaRx Site #1005

    Nantes, France

  • InflaRx Site #1009

    Nantes, France

  • InflaRx Site #1003

    Nice, France

  • InflaRx Site #1001

    Paris, France

  • InflaRx Site #1004

    Paris, France

  • InflaRx Site #1006

    Paris, France

  • InflaRx Site #1008

    Paris, France

  • InflaRx Site #1012

    Saint-Etienne, France

  • InflaRx Site #1002

    Suresnes, France

  • InflaRx Site #0201

    Aachen, Germany

  • InflaRx Site #0207

    Augsburg, Germany

  • InflaRx Site #0202

    Berlin, Germany

  • InflaRx Site #0208

    Dresden, Germany

  • InflaRx Site #0204

    Essen, Germany

  • InflaRx Site #0203

    Greifswald, Germany

  • InflaRx Site #0205

    Hanover, Germany

  • InflaRx Site #0206

    Jena, Germany

  • InflaRx Site #0502

    Chihuahua City, Mexico

  • InflaRx Site #0503

    Culiacán, Mexico

  • InflaRx Site #0506

    Mérida, Mexico

  • InflaRx Site #0504

    Monterrey, Mexico

  • InflaRx Site #0501

    Nuevo León, Mexico

  • InflaRx Site #0505

    Veracruz, Mexico

  • InflaRx Site #0101

    Amsterdam, Netherlands

  • InflaRx Site #0103

    Amsterdam, Netherlands

  • InflaRx Site #0106

    Eindhoven, Netherlands

  • InflaRx Site #0104

    Enschede, Netherlands

Showing 40 of 48 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.